



EVM Contributes to Council of Europe Hearing on “The Handling of The H1N1 Pandemic: More Transparency Needed?”

BRUSSELS, Belgium - 26 January 2010 – The European Vaccine Manufacturers group (EVM) welcomed the opportunity to address today’s Council of Europe Health Committee hearing on ‘The handling of the H1N1 pandemic: more transparency needed?’ EVM was pleased to provide information on industry’s role in helping combat pandemic influenza, and sought to address many of the misunderstandings that exist regarding the pandemic planning process. The EVM rejected allegations of inappropriate behaviour by vaccine producers during the response to H1N1 influenza, and provided additional clarity in three key areas:

1. Vaccine manufacturers responded to the requirements of public health authorities and national governments;
2. Industry responded quickly and effectively and was able to deliver vaccines ordered by governments;
3. Pandemic vaccines were properly developed and tested, and have been safely used in millions of European citizens.

EVM members remain committed to provide the Council of Europe’s Committee with further information if required.

[EVM full statement at the Council of Europe](#)

For further information please contact:

Colin Mackay
Director Communication & Partnerships, EFPIA
Email: colinmackay@efpia.org
Tel.: +32.2.626.2557
Fax: +32.2.626.2566
Web: <http://www.efpia.eu>

Magdalena de Azero
EVM Executive Director
Email: mra@efpia.org
Tel.: +32.2.626.2543
Fax: +32.2.626.2566
Web: <http://www.evm-vaccines.org/>

For more information please visit:

[The Council of Europe Website](#)

[The EVM Website](#)

EVM member companies are major suppliers of vaccines worldwide, producing the majority of vaccine doses in Europe. EVM members are: Baxter, Crucell, GlaxoSmithKline Biologicals, MedImmune, Novartis Vaccines, sanofi pasteur, sanofi pasteur MSD, Solvay Biologicals, and Wyeth Vaccines